| Assessment Status | Pre submission consultation scheduled |
| HTA ID | 24039 |
| Drug | Sodium Zirconium Cyclosilicate |
| Brand | Lokelma® |
| Indication | Sodium Zirconium Cyclosilicate is indicated for the treatment of hyperkalaemia in adult patients. |
| Assessment Process | |
| Rapid review commissioned | 01/10/2024 |
| Rapid review completed | 06/11/2024 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of SZC for this indication compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/11/2024 |
